SCHEMBL8333405

SCHEMBL8333405

NN1C=CNc2ccccc21

nearest known ligand 0.31

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
TLR9 Q9NR96 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7345762 0.76 GAA (0.34) GAASMN1; SMN2
SCHEMBL3120276 0.76 GAA (0.31) GAASMN1; SMN2
SCHEMBL1598178 0.76 GAA (0.31) GAASMN1; SMN2
SCHEMBL4372136 0.76 BRPF1 (0.36) GAASMN1; SMN2
SCHEMBL7603127 0.74
SCHEMBL212380 0.72 LMNA (0.38) GAASMN1; SMN2
SCHEMBL8335822 0.72 KDM4E (0.36) GAASMN1; SMN2TLR9
SCHEMBL29515039 0.72 KDM4E (0.36) GAASMN1; SMN2TLR9
SCHEMBL9742171 0.71 GAA (0.40) GAA
SCHEMBL8338720 0.71 GAA (0.32) GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107454900-A Novel imidazo [1,2-A ] quinoxalines and derivatives thereof for the treatment of cancer 蒙彼利埃大学 2017-12-08 CN claimed
WO-2016199943-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-15 WO claimed
CN-102413831-B Substituted imidazoquinoxalines BAYER SCHERING PHARMA AG 2014-06-04 CN claimed
CN-102413831-A Substituted imidazoquinoxalines BAYER SCHERING PHARMA AG 2012-04-11 CN claimed
CN-100386326-C 1-hydroxymethyl imidazo [1, 2-a ] quinoxaline compound and application thereof INST OF TOXIC PHARMACOLOGY ACA (CN) 2008-05-07 CN claimed
CN-1609105-A 1-hydroxymethyl imidazo [1, 2-alpha ] quinoxaline compound and application thereof INST OF TOXIC PHARMACOLOGY ACA (CN) 2005-04-27 CN claimed
WO-1999009845-A1 IMIDAZOQUINOXALINE PROTEIN TYROSINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 1999-03-04 WO claimed
EP-0104445-A2 Piperidinoquinoxaline derivatives, their preparation and use BOEHRINGER INGELHEIM KG (DE) 1984-04-04 EP claimed
WO-2025077857-A1 USE OF PRMT5 INHIBITOR IN TREATMENT OF TUMORS OR CANCERS 上海湃隆生物科技有限公司 2025-04-17 WO disclosed
WO-2024067433-A1 NOVEL PRMT5 INHIBITOR AND USE THEREOF 上海湃隆生物科技有限公司 2024-04-04 WO disclosed
CN-107454900-B Novel imidazo [1,2-A ] quinoxalines and derivatives thereof for the treatment of cancer 蒙彼利埃大学 2020-08-07 CN disclosed
EP-3240789-B1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER UNIV MONTPELLIER (FR) 2020-07-29 EP disclosed
CN-107454900-A Novel imidazo [1,2-A ] quinoxalines and derivatives thereof for the treatment of cancer 蒙彼利埃大学 2017-12-08 CN disclosed
WO-2016199943-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-15 WO disclosed
CN-1609105-A 1-hydroxymethyl imidazo [1, 2-alpha ] quinoxaline compound and application thereof INST OF TOXIC PHARMACOLOGY ACA (CN) 2005-04-27 CN disclosed
WO-1999009845-A1 IMIDAZOQUINOXALINE PROTEIN TYROSINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 1999-03-04 WO disclosed
EP-0647137-A4 GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF. UNIV CALIFORNIA WEBER ECKARD (US) 1998-09-16 EP disclosed
EP-0647137-A1 GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1995-04-12 EP disclosed
US-4539323-A HYPOTENSIVE AGENTS BOEHRINGER INGELHEIM KG (DE) 1985-09-03 US disclosed
EP-0104445-A2 Piperidinoquinoxaline derivatives, their preparation and use BOEHRINGER INGELHEIM KG (DE) 1984-04-04 EP disclosed